Skip to main
LFMD

LifeMD (LFMD) Stock Forecast & Price Target

LifeMD (LFMD) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

LifeMD is a direct-to-patient healthcare company that provides convenient and cost-effective virtual medical care and pharmacy services. Despite reporting lower than expected revenue and adjusted EBITDA in 2Q26, the company made significant investments in new initiatives such as transitioning to branded GLP-1s and expanding into women's health, highlighting its commitment to sustainable long-term growth. With a strong cash position and a growing telehealth platform, LifeMD seems well-positioned to capitalize on the demand for direct-to-consumer healthcare services.

Bears say

LifeMD is facing challenges with obtaining a positive ROI from its investments, impacting profitability and leading to a miss in topline for Q2 2026 and a lowering of FY2026 revenue guidance. While the recent FDA committee decisions are expected to provide a boost, they will not significantly contribute until 2027. The company also faced pressures in Q2, with high CACs and competition in the weight loss market, but potential growth in other product categories.

LifeMD (LFMD) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LifeMD and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LifeMD (LFMD) Forecast

Analysts have given LifeMD (LFMD) a Strong Buy based on their latest research and market trends.

According to 7 analysts, LifeMD (LFMD) has a Strong Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LifeMD (LFMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.